Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blind, Placebo-controlled, 5-arm, Parallel-group Trial to Assess Rotigotine Transdermal System Dose Response in Subjects With Advanced-stage Parkinson's Disease.

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled, 5-arm, Parallel-group Trial to Assess Rotigotine Transdermal System Dose Response in Subjects With Advanced-stage Parkinson's Disease.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rotigotine (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors Schwarz BioSciences; UCB
  • Most Recent Events

    • 08 Jun 2017 Results of post hoc analysis of pooled data from 6 placebo contolled trials (SP506, SP512, SP513, SP515, SP650, and SP921) presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
    • 08 Jun 2017 Results of post-hoc pooled analysis from patients who received levodopa doses in 8 randomized placebo-controlled studies, presented at the 21st International Congress of Parkinson's Disease and Movement Disorders.
    • 12 Feb 2016 Results of pooled post-hoc analysis of this and two other trials (see profile 169511 and 10814) published in the Clinical Neuropharmacology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top